Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The role of regulatory T cells in neurodegenerative diseases.
Cortical pathology in multiple sclerosis: experimental approaches to studies on the mechanisms of demyelination and remyelination.
Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS.
Life-threatening asthma attack during prolonged fingolimod treatment: case report.
Review: the role of vitamin D in nervous system health and disease.
The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.
Effects of non-steroidal antiinflammatory drugs on D-serine-induced oxidative stress in vitro.
Lack of response to rituximab therapy in patients with neuromyelitis optica: Response to Kim and Kim.
Lysoglycerophospholipids in chronic inflammatory disorders: The PLA(2)/LPC and ATX/LPA axes.
Alpha-tocopherol and MRI Outcomes in Multiple Sclerosis - Association and Prediction.
A Genome-Wide Integrative Genomic Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1).
Early detection of MS treatment complication may improve survival
Soluble adenylyl cyclase is necessary and sufficient to overcome the block of axonal growth by myelin-associated factors.
Cyclical suicidal ideation following natalizumab infusion for multiple sclerosis.
Aspirin and multiple sclerosis.
T-bet or not T-bet: Taking the last bow on the autoimmunity stage.
[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy.
CCSVI is associated with multiple sclerosis.
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Training in MS: influence of two different endurance training protocols (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial.
[Optic neuritis: diagnosis, treatment and clinical implications].
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Iranian family caregivers' challenges and issues in caring of multiple sclerosis patients: A descriptive explorative qualitative study.

Pages